DNDi has various types of agreements with its partners worldwide, such as Research Services Agreements, Material Transfer Agreements, Research and License Agreements, Collaboration Agreements, Clinical Trial Agreements, Financial Agreements, etc.

Research Services Agreements regulate contractual relationship between research service providers and DNDi. Material Transfer Agreements provide access to compounds for testing. In addition to these agreements, DNDi seeks to conclude Research and License Agreements with key partners which involve a greater commitment from both parties. The core of these agreements concern IP ownership (generally owned by the partner and in some cases co-owned), and licensing clauses. Several conditions are required to ensure availability and affordability of the treatment and respect of DNDi’s IP policy objectives. As a not-for-profit and patient-needs driven organization, DNDi seeks transparency to efficiently address urgent patient needs. Therefore, the licenses should be:

  • Royalty-free to ensure the lowest possible price
  • Sub-licensable, or in other terms, contain the authorization to disclose the obtained information to another party in order to continue product development
  • Worldwide coverage both for R&D and for manufacture
  • Non-exclusive to enable third parties to enter the field (included in our most innovative agreements)

An important objective for DNDi’s agreement is limited confidentiality – to make available all information generated on the product during its development in the form of publications or databases.

 

Pharmaceuticals

AbbVie (USA) – Projects: Screening / Lead optimization / Leish H2L / Chagas H2L  / Chagas C205 Series / Flubendazole Macrofilaricide / AbbV4083 / ‘4-in-1’ LPV/r/ABC/3TC

Astellas Pharma (Japan) – Projects: Screening

AstraZeneca (UK) – Projects: ScreeningLead optimization/ Leish H2L / Chagas H2L

Avista Pharma (formerly SCYNEXIS) (USA) – Projects: Acoziborole / SCYX-1330682 SCYX-1608210 / DNDi-5421 DNDi 5610

Bayer Healthcare (Germany) – Projects: ScreeningEmodepside

Bristol-Myers Squibb (USA) – Projects: Screening

Cipla Inc. (India) – Projects: ‘4-in-1’ LPV/r/ABC/3TC / LPV/r pellets with dual NRTI / ASMQ

Daiichi Sankyo (Japan) – Projects: Screening / Daiichi Sankyo LH2L / Daiichi Sankyo CH2L

Debiopharm (Switzerland) – Projects: Discovery

 DuPont (formerly E.I du Pont Nemours) (USA) – Projects: Screening

Eisai Co., Ltd. (Japan) – Projects: Screening  /  Leish H2L / Chagas H2L / Azoles E1224New benz regimens +/- fosravuconazole / Fosravuconazole

Eurofins Optimed (France) – Projects: Fexinidazole-Miltefosine combination

Farmanguinhos (Fiocruz) (Brazil) – Projects: ASMQ

GeneDesign Inc. (Japan) – Projects: CpG-D35

Gilead Sciences (USA) – Projects: Fexinidazole (HAT) 

GlaxoSmithKline (GSK) (Spain) – Projects: Screening / Lead optimization / Leish H2L / New treatments for HIV/VL / Chagas C205 series / Chagas H2L 

Genomics Institute of the Novartis Research Foundation (GNF Novartis), Genomics Institute of the Novartis Research Foundation (USA) – Projects: Screening

Humax Pharmaceutical (Colombia) – Projects: Anfoleish

Johnson & Johnson (USA) – Projects: ScreeningFlubendazole Macrofilaricide

Janssen (Belgium) – Projects: Screening

Janssen Research & Development (USA) – Projects: Flubendazole Macrofilaricide

LAFEPE (Brazil) – Projects: Paediatric dosage form of benznidazole

Mercachem (The Netherlands) – Projects: Screening

Merck (USA) – Projects: Screening / Lead optimization / Leish H2L / Chagas H2L

Merck Serono (Germany) – Projects: Screening

Paladin Labs (Canada) – Projects: VL-0208

Pharco Pharmaceuticals Inc. (Egypt) – Projects: Ravidasvir/ Sofosbuvir

Pfizer Ltd. (UK) – Projects: Screening / Lead optimization/ Aminopyrazoles

Presidio Pharmaceuticals, Inc. (USA) – Projects: Ravidasvir/Sofosbuvir

Sanofi (France) – Projects: Screening / Lead optimization/ Leish H2L / Chagas H2L / Chagas C205 series / ASAQ / Fexinidazole (HAT) 

Sanofi-Chinoin (Hungary) – Projects: Fexinidazole-Miltefosine combination

Boehringer Ingelheim, Animal Health Business Unit (formerly Sanofi Merial) (USA) – Projects: Screening 

Sara Pharm (Romania) – Projects: DNDi-6148

Shionogi & Co. Ldt (Japan) – Projects: Screening / Leish H2L / Chagas H2L

Syngene (India) – Projects: DNDi-6148 / DNDi-0690

Takeda Pharmaceutical Company Ltd. (Japan) – Projects: Screening / Aminopyrazoles /  Leish H2L / Chagas H2L / DNDi-5561

Zenufa Laboratories Ltd (Tanzania) – Projects: ASAQ

 Zoetis (formerly Pfizer Animal Health) (USA) – Projects: Screening

top of the page

 

Biotechs

 Abzena (formerly Polytherics) (UK) – Projects: Formulation of amphotericin B, in collaboration with Imperial College.

Anacor Pharmaceuticals (USA) – Projects: Screening / Lead optimization / SCYX-1330682 SCYX-1608210 / Leish H2L / DNDi-5421 DNDi-5610 / Acoziborole / DNDi-6148 / Oxachagas / Chagas C205 series

 BioAscent (UK) – Projects: Screening

Celgene Global Health (USA) – Projects: Screening / Lead optimization / CGH VL series 1 / Chagas C205 series

Evolva (Switzerland) – Projects: Discovery

 iThemba Labs (South Africa) – Projects: Lead optimization

 Sanofi Genzyme (formerly Genzyme) (USA) – Projects: Material transfer for research and development on HAT, Chagas disease, and leishmaniasis.

SCYNEXIS Inc. (USA) – Projects:  Lead optimization /  SCYX-2035811 / SCYX-1330682 SCYX-1608210 / Acoziborole / DNDi-5421 DNDi-5610 / DNDi-6148

Sequella, Inc. (USA) – Projects: Screening

 Thermosurgery Technologies Inc. (USA) – Projects: New CL combination therapies

Vertex (USA) – Projects: Screening

top of the page

 

Universities

Addis Ababa University (Ethiopia) – Projects: VL-0208New treatments for HIV/VL / SSG&PM

 Chiang Mai University, Associated Medical Sciences/PHPT International Research Unit (Thailand) – Projects: LPV/r pellets with dual NRTI

Banaras Hindu University, Institute of Medical Sciences (India) – Projects: New treatments for PKDL

Baylor College of Medicine Children’s Foundation (Uganda) – Projects: LPV/r pellets with dual NRTI

Centres d’Investigation Clinique des Centres Hospitaliers Universitaires de Clermont-Ferrand (France) – Projects: Fexinidazole-Miltefosine combination

Free University Amsterdam (The Netherlands) – Projects: Fosravuconazole

Fundacao de Apoio Universidade Federale de Sao Paolo (FapUnifesp) (Brazil) – Projects: Lead optimization / Leish H2L / Chagas H2L / Chagas C205 series

Gondar University Hospital (Ethiopia) – Projects: VL-0208 / Miltefosine-Paromomycin combination for AfricaNew treatments for HIV/VL / SSG&PM 

 Griffith University (Australia) – Projects: Leish H2L / Chagas H2L / Chagas C205 series 

Imperial College London (UK) – Projects: Formulation of amphotericin B with Polytherics.

 Liverpool School of Hygiene and Tropical Medicine (LSTM) (UK) – Projects: ABBV-4083

London School of Hygiene and Tropical Medicine (UK) – Projects: Screening / Lead optimization/ Aminopyrazoles / VL-0208 / VL-2098DNDi-5421 DNDi-5610 / CGH VL series 1Leish H2L / DNDi-6148 / DNDi-0690 / Fexinidazole-Miltefosine combination / New treatments for HIV/VL / SSG&PM / New VL treatments Asia / Nitroimidazole / OxachagasChagas H2L / Biomarkers /  Chagas C205 series

Mahidol UniversityShoklo Malaria Research Unit (SMRU) (Thailand) – Projects: ASMQ / ASAQ

Makarere University (Uganda) – Projects: Fexinidazole-Miltefosine combination / SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa

McGill University (Canada) – Projects: Biomarkers / Flubendazole Macrofilaricide

Michigan State University (USA) – Projects: Flubendazole Macrofilaricide

Monash University, Centre for Drug Candidate Optimization (Australia) – Projects: Lead optimization / Fenarimol / Chagas H2L / Leish H2L / Chagas C205 series

Murdoch University, School of Veterinary and Biomedical Science (Australia) – Projects: Fenarimol series (Chagas) / Nitroimidazole (Chagas) / Lead Optimization / Chagas C205 series

Nagasaki University (Japan) – Projects: CpG-D35

Ohio State University (USA) – Projects: CpG-D35

 Osaka University (Japan) – Projects: CpG-D35

Pace University (USA) – Projects: SCYX-2035811 / SCYX-1330682 SCYX-1608210

Radboud University Medical Center (The Netherlands) – Projects: Fosravuconazole

Stellenbosch University (South Africa) – Projects: Superbooster therapy paediatric HIV/TB

 UCL School of Pharmacy (formerly London School of Pharmacy) (UK) – Projects: Formulation of amphotericin B, in collaboration with Imperial College.

Universidad Autónoma Juan Misael Saracho (Bolivia) – Projects: Biomarkers / Azoles E1224New benz regimens +/- fosravuconazole regimens / Fexinidazole (Chagas)

 Universidade de Brasilia (Brazil) – Projects: New VL treatments Latin America

Universidade Estadual de Campinas UNICAMP (Brazil) – Project: Lead Optimization / Leish H2L / Chagas H2L / Chagas C205 series

Universidade Estadual de Montes Claros (Brazil) – Projects: New VL treatments Latin America

Universidade Federal de Ouro Preto (Brazil) – Projects: Fenarimol / Nitroimidazole / Lead Optimization

 Universidade Federal de Piauí (Brazil) – Projects: New VL treatments Latin America

 Universidade Federal de Sergipe (Brazil) – Projects: New VL treatments Latin America

 University Hospital of Bonn, Institute of Medical Microbiology, Immunology and Parasitology (Germany) – Projects: Screening / Macro Filaricide 3 

Universidad Mayor de San Simon (Bolivia) – Projects: Biomarkers / Azoles E1224New benz regimens +/- fosravuconazole regimens / Fexinidazole (Chagas)

Universidad Peruana Cayetano Heredia (Peru) – Projects: New CL combination therapies

Universidad Nacional de San Martin (Argentina) – Projects: Biomarkers 

 Universidad São Paolo (USP) (Brazil) – Projects: Chagas H2L

Universidade do Estado do Rio de Janeiro (Brazil) – Projects: New VL treatments Latin America

Université de Bordeaux, Faculté de Pharmacie (France) – Projects: ASAQ

University de Antioquia, Programa de Estudio y Control de Enfermedades Tropiales (PECET) (Colombia) – Projects: Anfoleish / New CL combination therapies

University of Antwerp, Laboratory of Microbiology, Parasitology and Hygiene (Belgium) – Projects: Screening / Lead optimization  / Leish H2L / Chagas H2L / SCYX-1330682 SCYX-1608210 / DNDi-5421 DNDi-5610 / Aminopyrazoles / DNDi-6148 / DNDi-0690VL-0208 / CGH VL series 1  / Nitroimidazole / OxachagasChagas C205 series

 University of Auckland (New Zealand) – Projects: Lead optimization / SCYX-2035811 / Nitroimidazole / DNDi-0690

 University of Buea (Cameroon) – Projects: Flubendazole Macrofilaricide

University of Cape Town, Division of Clinical Pharmacology Department of Medicine (South Africa) – Projects: ScreeningSuperbooster therapy paediatric HIV/TB

University of Dundee, Drug Discovery Unit (UK) – Projects: Screening / Leish H2L / Chagas H2L / Chagas C205 series

University of Gedaraf (Sudan) – Projects: New treatments for PKDL

University of Nairobi (Kenya) – Projects: LPV/r pellets with dual NRTI

 University of Witswatersrand, Perinatal HIV Research Unit (South Africa) – Projects: Superbooster therapy Paediatric HIV/TB

University of Texas at El Paso (USA) – Project: Biomarkers

Uppsala University (Sweden) – Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL / New treatments for PKDL / Miltefosine-Paromomycin combination for Africa

Utrecht University (The Netherlands) – Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL co-infectionMiltefosine-Paromomycin combination for Africa

Various academic partners (South Africa and Kenya) – Projects: ‘4-in-1’ LPV/r/ABC/3TC

 University of California (UCSF) (USA) – Projects: K777Superbooster therapy Paediatric HIV/TB

University of North Carolina, Office of Technology Development (USA). Since 2007, DNDi partner through information sharing and discovery for NTDs.

University of Oxford, Worldwide Antimalarial Drug Resistance Network (UK) – Projects: ASAQ (Malaria) / ASMQ (Malaria)

University Sains Malaysia (USM) (Malaysia) – Projects: ASAQ (Malaria) / ASMQ (Malaria)

top of the page

 

University “Spin-off”

Epichem (Australia) – Projects: Screening / Leish H2LChagas H2L / Lead optimization / Fenarimol / Chagas C205 series

Eskitis Institute for Cell and Molecular Therapies, Griffith University (Australia) – Projects: ScreeningLead optimization/ Chagas H2L / Leish H2L / Chagas C205 series

top of the page

 

Research Institutes

Broad Institute, MIT and Harvard (USA) – Projects: Discovery activity for Chagas disease

 Fundacion Para el Estudio de las Infecciones Parasitarias y enfermedad de Chagas (FIPEC) (Argentina) Projects: Clinical studies for Chagas disease.

Georges Institute for Global Health (Australia) – Projects: ASAQ

Ifakara Health Institute (Tanzania) – Projects: ASMQ

IMEA Consulting France: Institut de Médecine et d’Epidémiologie Appliquée, Département de Santé Tropicale (France) – Projects: ASAQ

Institut de Recherche pour le Développement (IRD) (France) – Projects: Acoziborole / Fexinidazole (HAT) 

 Institut de Recherche pour le Développement (IRD) (Sénégal) – Projects: ASAQ

Institut National de Recherche Biomédicale (DRC) – Projects: Acoziborole / Fexinidazole (HAT) 

Institut Pasteur (France) – Projects: Screening

 Institut Pasteur Korea (South Korea) – Projects: Screening / Leish H2LChagas H2L / Fenarimol / Chagas C205 series

Institute of Tropical Medicine Antwerp (Belgium) – Projects: Acoziborole/ Fexinidazole (HAT) / New treatments for HIV/VL  / VL-0208 / New VL treatments Asia

 Institute of Endemic Disease (IEND), Khartoum University (Sudan), Leishmaniasis East Africa Platform (LEAP) – Projects: VL-0208 / SSG&PM / Fexinidazole-Miltefosine combination / New treatments for PKDL / Fosravuconazole / Miltefosine-Paromomycin combination for Africa 

Instituto Nacional de Epidemiología Dr Fatala Cháben (Argentina) – Projects: Biomarkers / New benz regimens +/- fosravuconazole  / Paediatric dosage form of benznidazole

Instituto de Salud Carlos III (Spain) – Projects: New treatments for PKDL 

Kenya Medical Research Institute (Kenya) – Projects: Fexinidazole-Miltefosine combination / Miltefosine-Paromomycin combination for Africa / LPV/r pellets with dual NRTI / SSG&PM / ASAQ / ASMQ

KIT (Kononklijk Instituut voor de Tropen) Royal Tropical Institute (The Netherlands) – Projects: VL-0208 / Fexinidazole-Miltefosine combination

Leti, CEA (France) – Projects: Biomarkers

Luxembourg Institute of Health (Luxembourg) – Projects: New benz regimens +/- fosravuconazole Fexinidazole (Chagas) / Acoziborole 

Medical Research Council (MRC) (UK) – Projects: ‘4-in-1’ LPV/r/ABC/3TC

National Institutes of Health (USA) – Projects: Screening / CpG-D35

Necker Institute (France) – Projects: ‘4-in-1’ LPV/r/ABC/3TC

Northwick Park Institute for Medical Research (UK) – Projects: Screening / Macro Filaricide 3

Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) (India) – Projects: New treatments for PKDL / New VL treatments Asia

Shandukani Research Centre Wits Reproductive Health and HIV Institute (South Africa) – Projects: Superbooster therapy paediatric HIV/TB

The Netherlands Cancer Institute (The Netherlands) – Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL / VL-0208 / New treatments for PKDL / Miltefosine-Paromomycin combination for Africa

The Swiss Tropical and Public Health Institute (Switzerland) – Projects: Screening / Leish H2LChagas H2L / Acoziborole / Fexinidazole (HAT) / NECT / SSG&PM / LPV/r pellets with dual NRTI

University of Georgia Research Foundation (USA) – Projects: Biomarkers

University of Georgia, The Center for Tropical and Emerging Global Diseases (CTEGD) (USA) – Projects: Azoles E1224

Walter Reed Army Institute (USA) – Projects: Screening

top of the page

 

National Research Centres

Administración Nacional de Laboratorios e Institutos de Salud (ANLIS)Centro Nacional de Diagnóstico e Investigación de Endemo-epidemias (Argentina) – Projects: Paediatric dosage form of benznidazole 

B.P Koirala Institute of Health Sciences (Nepal) – Projects: Clinical trials for visceral leishmaniasis.

 Brazilian Biosciences National Laboratory (LNBio), Centro Nacional de Pesquisa em Energia e Materiais (CNPEM) (Brazil) – Projects: Screening / Lead optimization / Chagas H2L / Chagas C205 series

 Centre National de Recherche et de Formation sur le Paludisme (CNRFP) (Burkina Faso) – Projects: ASMQ

 Central Drug Research Institute (CDRI) (India) – Projects: VL-2098 / DNDi-0690

 Council of Scientific and Industrial Research (CSIR) (India) – Projects: Various partnerships for leishmaniasis and HAT through screening and discovery activities of anti-leishmaniasis compounds.

Erasmus Medical Centre (The Netherlands) – Projects: Fosravuconazole

Fiocruz, Fundaçao Oswaldo Cruz (Brazil) – Projects: Azoles E1224

Indian Council of Medical Research (ICMR) (India) – Projects: New VL treatments Asia / ASAQ / ASMQ

 Instituto Rene Rachou, Fiocruz Minas (Brazil) – Projects: New VL treatments Asia / New VL treatments Latin America

International Centre for Diarrhoeal Disease Research (icddr,b) (Bangladesh) – Projects: New treatments for PKDL / New VL treatments Asia

IS Global, Centre de Recerca en Salut Internacional de Barcelona (CRESIB) (Spain) – Projects: Screening /  Biomarkers / New benz regimens +/- fosravuconazole / Fexinidazole (Chagas)Azoles E1224

Joint Clinical Research Centre (Uganda) – Projects: LPV/r pellets with dual NRTI

Kala Azar Medical Research Centre (India) – Projects: New treatments for PKDL / New VL treatments Asia

Mycetoma Research Centre, Soba University Hospital (Sudan) – Projects: Fosravuconazole

National Institute for Medical Research (NIMR) (Tanzania) – Projects: ASMQ

 National Institute of Pathology (India) – Projects: New treatments for PKDL

National Vector Borne Disease Control Programme (India) – Projects: New VL treatments Asia

Novartis Centre de la Recherche Santé Animale (Switzerland) – Projects: Screening

Seattle Institute for Biomedical and Clinical Research (SIBCR) (USA) – Projects: Discovery for NTDs.

Texas Biomedical Research Institute (USA) – Projects: Biomarkers

top of the page

 

NGOs/IOs

AEDES, the European Agency for Development and Health, consulting company for social and public health sector (Belgium) – Projects: ASAQ

 AWOL (UK) – Projects: ABBV-4083

Clinton Health Access Initiative (USA) – Projects: LPV/r pellets with dual NRTI

Collective of Applied Studies and Social Development (CEADES) (Bolivia) – Projects: Azoles E1224 / New benz regimens +/- fosravuconazole / Fexinidazole (Chagas)

Communauté Baptiste du Congo (CBCO) (Democratic Republic of Congo) – Projects: Fexinidazole (HAT)

Enhancing Care Foundation (ECF) (South Africa) – Projects: Superbooster therapy paediatric HIV/TB

Epicentre (France) – Projects: NECT / ASAQ / ASMQ

Epicentre Research Center (Uganda) – Projects: LPV/r pellets with dual NRTI

Family AIDS Care and Education Services (FACES) Project (Kenya) – Projects: LPV/r pellets with dual NRTI

Fundación Mundo Sano and ELEA (Argentina) – Projects: New benz regimens +/- fosravuconazole / Paediatric dosage form of benznidazole

IDA Foundation (The Netherlands) – Projects: VL-0208 / SSG&PM

i+solutions (The Netherlands) – Projects: VL-0208 / SSG&PM / New treatments for PKDL

 Management and Development for Health (MDH) (Tanzania) – Projects: LPV/r pellets with dual NRTI

Médecins Sans Frontières – Projects: ASAQ  / NECT / Fexinidazole (HAT) / Fexinidazole-Miltefosine combination  / New treatments for HIV/VL  / VL-0208 / New VL treatments Asia / SSG&PM  / Generic Ambisome /  Biomarkers / Azoles E1224 / Fexinidazole (Chagas) / ‘4-in-1’ LPV/r/ABC/3TC 

Microbial Chemistry Research Foundation (Japan) – Projects: Screening

 Offre Technique d’Etude et de Coopération Internationale (OTECI) (France) – Projects: ASMQ

Royal Society of Chemistry (UK): MoU to promote open source discovery.

UNITAID (Switzerland) – Projects: ‘4-in-1’ LPV/r/ABC/3TC / LPV/r pellets with dual NRTI

WHO-TDR: (Switzerland) – Projects: ASAQ / ASMQ / Screening / New VL treatments Asia

top of the page

 

PDPs/PPPs

FIND, Foundation for Innovative New Diagnostics (Switzerland) – Projects: Collaboration and material transfer agreement to develop an ELISA-based diagnostic test for leishmaniasis. MoU for collaboration in the field of neglected tropical diseases.

 Lygature (formerly TI Pharma) (The Netherlands) – Projects: DNDi partner for discovery activities.

Medicines for Malaria Venture (MMV) (Switzerland) – Projects: Screening / ASAQ / ASMQ

Novartis Institute for Tropical Diseases (Singapore) – Projects: Lead optimization

 Institute for One World Health (OWH) (USA) – Projects: VL-0208 / New VL treatments Asia / SSG&PM

TB Alliance (USA) – Projects: NitroimidazoleSCYX-2035811 / VL-2098 / Screening / Lead optimization/ DNDi-0690

top of the page

 

Hospitals

Amsterdam Medical Center (The Netherlands) – Projects: Miltefosine-Paromomycin combination for Africa

Amudat General Hospital (Uganda) – Projects: Fexinidazole-Miltefosine combination / SSG&PM / Miltefosine-Paromomycin combination for Africa

Arba Minch Hospital (Ethiopia) – Projects: SSG&PM

CHUV, Centre Hospitalier Universitaire Vaudois (Switzerland) – Projects: ASMQ

Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital (South Africa) – Projects: Superbooster therapy paediatric HIV/TB

Gertrude’s Children’s Hospital (Kenya) – Projects: LPV/r pellets with dual NRTI

Hospital de Niños de Jujuy (Argentina) – Projects: Paediatric dosage form of benznidazole 

Hospital de Niños Dr. Ricardo Gutiérrez (Argentina) – Projects: Paediatric dosage form of benznidazole / New benz regimens +/- fosravuconazole

Hospital de Sant Joan Despí Moisès Broggi, Consorci Sanitari Integral (Spain) – Projects: Fexinidazole (Chagas)

Hospital General Universitari de Valencia (Spain) – Projects: New benz regimens +/- fosravuconazole / Fexinidazole (Chagas)

Hospital Independencia, Centro de Chagas y Patologia Regional (Argentina) – Projects: Paediatric dosage form of benznidazole / New benz regimens +/- fosravuconazole

Hospital Público Materno Infantil (Argentina) – Projects: Paediatric dosage form of benznidazole

Hospital Sao José de Doencas Infecciosas (Brazil) – Projects: New VL treatments Latin America

 Kacheliba District Hospital (Kenya) – Projects: Fexinidazole-Miltefosine combination / Miltefosine-Paromomycin combination for Africa

 KATH, Komfo Anokye Teaching Hospital (Ghana) – Projects: ASAQ

 Kenyatta National Hospital (KNH) (Kenya) – Projects: LPV/r pellets with dual NRTI

Mbagathi District Hospital (Kenya) – Projects: LPV/r pellets with dual NRTI

Moi Teaching and Referral Hospital (Kenya) – Projects: LPV/r pellets with dual NRTI

 Muzaffarpur Hospital (India) – Projects: New treatments for PKDL

 National Museum of Natural History Paris (MNHN) (France) – Projects: Screening

Paediatric Hospital Joao Paulo II – FHEMIG (Brazil) – Projects: New VL treatments Latin America

Shaheed Suhrawardy Medical College and Hospital (Bangladesh) – Projects: New VL treatments Asia

SK Hospital Mymensingh (Bangladesh) – Projects: New treatments for PKDL

St. Lumumba Health Centre (Kenya) – Projects: LPV/r pellets with dual NRTI

Tygerberg Children’s Hospital (South Africa) – Projects: Superbooster therapy paediatric HIV/TB

 Vall d’Hebron University Hospital (Spain) – Projects: Fexinidazole (Chagas)

University Hospitals of Geneva (HUG) (Switzerland) – Projects: Biomarkers / Macro Filaricide 3

top of the page

 

Ministries of Health/Governmental Organizations

Gedarif MoH (Sudan). Leishmaniasis East Africa Platform (LEAP) – Projects: Various partnerships for clinical trials in the field of leishmaniasis / VL-0208 / SSG&PM

Bihar State Health Society (India) – Projects: New VL treatments Asia

Centre for Disease Control and Prevention CDC/President’s Emergency Plan for AIDS Relief (USA) – Projects: ‘4-in-1’ LPV/r/ABC/3TC

 Centro Nacional de Diagnostico e Investigacion de Endemo-epidemias (CeNDIE), Ministry of Health (Argentina) – Projects: Paediatric dosage form of benznidazole

Clinical Research Malaysia, Ministry of Health (Malaysia) – Projects: Ravidasvir/Sofosbuvir

Department of Health and Department of Science and Technology (South Africa) – Projects: Superbooster therapy paediatric HIV/TB

Department of Health South Africa (South Africa) – Projects: ‘4-in-1’ LPV/r/ABC/3TC / LPV/r pellets with dual NRTI

 Food & Drug Administration (FDA) (US) – Projects: CpG-D35

Ministry of Health, Leishmaniasis Control Programme (Brazil) – Projects: New VL treatments (Latin America)

 Ministry of Health, National Malaria Control Programme (Burundi) – Projects:  ASAQ

Ministry of Health (Cambodia) – Projects: ASMQ

Ministry of Health (DRC) – Projects: Various partnerships (financial and clinical trial agreement) in the field of HAT / NECT

Ministry of Health (Ethiopia) – Projects: SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa

Ministry of Health (Ghana) – Projects: ASAQ

Ministry of Health (Kenya) – Projects: LPV/r pellets with dual NRTI / SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa

Ministry of Health (Sierra Leone) – Projects: ASAQ

Ministry of Health (Sudan) – Projects: New treatments for PKDL / SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa

Ministry of Health (Uganda) – Projects: SSG&PM / VL-0208

Ministry of Health and Family Welfare (Bangladesh) – Projects: New VL treatments Asia

Ministry of Health and Ministry of Industry, Science and Technology (Thailand) – Projects: Ravidasvir/Sofosbuvir

Ministry of Health, Province of Jujuy (Argentina) – Projects: Paediatric dosage form of benznidazole

National Trypanosomiasis Control Programme (DRC) – Projects: NECT / Acoziborole 

 Programa Nacional de Leishmaniasis (Colombia) – Projects: New CL combination therapies 

top of the page

 

Contract Research Organizations (CROs)

Accelera (Italy) – Projects: VL-2098 / DNDi-0690 / DNDi-6148

Aptuit (Italy) –  Projects: DNDi-0690 / Fexinidazole-Miltefosine combination for Africa / VL-2098 / Fexinidazole (HAT)

BaseCon (Denmark) – Projects: Fexinidazole-Miltefosine combination for Africa  / New treatments for HIV/VL

Bertin Bioreagent (formerly Bertin Pharma) (France) – Projects: ASAQ (Malaria) / VL-2098Fexinidazole (HAT) / Acoziborole

 Bioclinica (formerly CoreLab Partners) (France) – Projects: Azoles E1224

 Biotrial (France) – Projects: Fexinidazole (HAT)

Cardiabase (Banook Group) (France) – Projects: Fexinidazole-Miltefosine combination for Africa / Fexinidazole (HAT) / Acoziborole 

Calvert Labs (USA) – Projects: Pre-clinical phase for topical formulation against cutaneous leishmaniasis.

Cardinal Health (formerly Cardinal System) (France) – Projects: Azoles E1224

Catalent (USA) – Projects: Screening, discovery, clinical activities as well as registration and regulatory issues in the field of malaria.

Centipharm (Axynthis Group) (France) – Projects: CMC/manufacture of fexinidazole for HAT.

Central Diagnostics (India) – Projects: Partner in the field of visceral leishmaniasis.

Certara (formerly Quantitative Solutions) (USA) – Projects: Azoles E1224

 Charles River (formerly WIL Research) (France) – Projects: DNDi-6148

Clinwin Research Services (Kenya) – Projects: ASMQ

Covance (UK) – Projects: VL-2098

Creapharm (France) – Projects: Fexinidazole (Chagas)

Drugabilis (France) – Projects: Screening & Lead Optimization / Fexinidazole (HAT) / Acoziborole / Flubendazole Macrofilaricide / VL-2098

Endolytics (USA) – Projects: VL-2098

 Envigo (formerly Harlan Laboratories and Huntingdon Life Sciences Limited) (Switzerland) – Projects: Pre-clinical research agreement for Chagas disease / VL-2098

 Eurofins Advinus (formerly Advinus Therapeutics Ltd.) (India) – Projects: Acoziborole / VL-2098 / DNDi-0690 

Eurofins Optimed (France) – Projects: Acoziborole / ‘4-in-1’ LPV/r/ABC/3TC / Fexinidazole (HAT) / DNDi-6148

 FP Clinical Pharma (Argentina) – Projects: New benz regimens +/- fosravuconazole

Frontage (USA) – Projects: Azoles E1224

GVK BIO (India) – Projects: Clinical phase for malaria and VL / New VL treatments Asia

Instituto de Investigaciones en Ingeniería Genética y Biología Molecular “Dr. Héctor N. Torres”, National Council of Scientific and Technological Research (INGEBI-CONICET) (Argentina) – Projects: New benz regimens +/- fosravuconazole  / Fexinidazole (Chagas) / Biomarkers /  Azoles E1224 / Paediatric dosage form of benznidazole

JSS Medical Research (Canada) – Projects: Anfoleish / Fexinidazole (Chagas)

LAT Research (Argentina) – Projects: Azoles E1224 / New benz regimens +/- fosravuconazole 

Nucleo de desenvolvimento farmacêutico e cosméticos  (NUDFAC) (Brazil) – Projects: Azoles E1224 / Paediatric dosage form of benznidazole / New benz regimens +/- fosravuconazole 

Patheon (UK) – Projects: Formulation development and manufacturing for HAT / Acoziborole

Penn Pharmaceuticals Services (UK) – Projects: Acoziborole / DNDi-0690

PhinC Development (France) – Projects: Fexinidazole-Miltefosine combination for Africa / Acoziborole / New benz regimens +/- fosravuconazole 

RCTs (France) – Projects: NECT / Fexinidazole (HAT) / Acoziborole

Roowin (France) – Projects: CMC activities for HAT.

Sandexis (UK) – Projects: Lead optimization/ Leish H2L / DNDi-5421 DNDi-5610 / Aminopyrazoles / CGH VL series 1 / Chagas H2L / DNDi-6148 / Chagas C205 serie / Oxachagas

Selcia (UK) Projects: VL-2098

Sigma-Aldrich (UK) – Projects: VL-2098

SGS (France) – Projects: Clinical study of fexinidazole for HAT, subsequently performing bioanalyses / Acoziborole / Fexinidazole (HAT)

SGS (Belgium) – Projects: Fexinidazole-Miltefosine combination for Africa / Fexinidazole (HAT)

 TCG Lifesciences (India) – Projects: Lead optimization/ Leish H2L / Chagas H2L / Chagas C205 serie

Theradis Pharma (France) – Projects: Fexinidazole (HAT) / Acoziborole

United BioSource Corporation (UBC) (Switzerland) – Projects: New treatments for HIV/VLFexinidazole-Miltefosine combination for Africa

WuXi AppTech (China) – Projects: Screening / Lead optimization / Leish H2L / DNDi-5421 DNDi-5610 / Aminopyrazoles / Oxachagas / Nitroimidazole / SCYX-2035811 / CGH VL series 1 / Chagas H2L / DNDi-6148 / DNDi-0690 / ‘4-in-1’ LPV/r/ABC/3TC / Chagas C205 serie 

top of the page

 

Platforms and Networks

HAT Platform – Projects: NECT / Fexinidazole (HAT) / Acoziborole

Leishmaniasis East Africa Platform (LEAP) – Projects: Fexinidazole-Miltefosine combination / New treatments for PKDL / New treatments for HIV/VL / SSG&PM / Fexinidazole-Miltefosine combination for Africa / VL-0208

National Control Programmes of the DRC and CAR – Projects: Fexinidazole (HAT)

NHEPACHA Network – Projects: Biomarkers

Platform of Integral Care for Patients with Chagas Disease (Bolivia) – Projects: New benz regimens +/- fosravuconazole / Fexinidazole (Chagas) / Azoles E1224

top of the page

 

 

Please contact us at partnership@dndi.org to propose collaborative projects.

top of the page